BRPI0820131A2 - Sphingosine-1-phosphate active oxadiazole derivatives (s1p) - Google Patents
Sphingosine-1-phosphate active oxadiazole derivatives (s1p)Info
- Publication number
- BRPI0820131A2 BRPI0820131A2 BRPI0820131A BRPI0820131A2 BR PI0820131 A2 BRPI0820131 A2 BR PI0820131A2 BR PI0820131 A BRPI0820131 A BR PI0820131A BR PI0820131 A2 BRPI0820131 A2 BR PI0820131A2
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- oxadiazole derivatives
- phosphate active
- phosphate
- active
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0725120A GB0725120D0 (en) | 2007-12-21 | 2007-12-21 | Compounds |
GB0821918A GB0821918D0 (en) | 2008-12-01 | 2008-12-01 | Compounds |
PCT/EP2008/067965 WO2009080725A1 (en) | 2007-12-21 | 2008-12-19 | Oxadiazole derivatives active on sphingosine-1-phosphate (sip) |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0820131A2 true BRPI0820131A2 (en) | 2015-05-12 |
Family
ID=40342566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0820131 BRPI0820131A2 (en) | 2007-12-21 | 2008-12-19 | Sphingosine-1-phosphate active oxadiazole derivatives (s1p) |
Country Status (29)
Country | Link |
---|---|
US (2) | US8222245B2 (en) |
EP (1) | EP2222669B1 (en) |
JP (1) | JP2011506569A (en) |
KR (1) | KR20100108566A (en) |
CN (1) | CN101945863B (en) |
AR (1) | AR069916A1 (en) |
AU (1) | AU2008339988B2 (en) |
BR (1) | BRPI0820131A2 (en) |
CA (1) | CA2710130A1 (en) |
CO (1) | CO6290646A2 (en) |
CR (1) | CR11579A (en) |
DK (1) | DK2222669T3 (en) |
DO (1) | DOP2010000194A (en) |
EA (1) | EA017691B1 (en) |
ES (1) | ES2434730T3 (en) |
HK (1) | HK1142062A1 (en) |
HR (1) | HRP20130957T1 (en) |
IL (1) | IL206235A0 (en) |
MA (1) | MA31924B1 (en) |
NZ (1) | NZ585996A (en) |
PE (1) | PE20091339A1 (en) |
PL (1) | PL2222669T3 (en) |
PT (1) | PT2222669E (en) |
RS (1) | RS53038B (en) |
SI (1) | SI2222669T1 (en) |
TW (1) | TWI415847B (en) |
UY (1) | UY31570A1 (en) |
WO (1) | WO2009080725A1 (en) |
ZA (1) | ZA201003963B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007026341A1 (en) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
PE20091057A1 (en) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | MINERALCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE |
GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
DE102007061963A1 (en) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | pyridazinone derivatives |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
DE102008019907A1 (en) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | pyridazinone derivatives |
GB0807910D0 (en) | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
DE102008028905A1 (en) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives |
ES2434247T3 (en) | 2008-12-22 | 2013-12-16 | Merck Patent Gmbh | Novel polymorphic forms of 6- (1-methyl-1H-pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] -benzyl dihydrogen phosphate } -2H-pyridazin-3-one and their manufacturing processes |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2011028927A1 (en) * | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
CN103649056B (en) | 2011-05-10 | 2016-04-27 | 吉利德科学公司 | As the condensed heterocyclic compouds of ion channel modulators |
CN102250035A (en) * | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | Synthesis method and medicinal purpose of diaryl substituted-1,3,4-oxadiazole compounds |
TW201837023A (en) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | Fused heterocyclic compounds as ion channel modulators |
NO3175985T3 (en) | 2011-07-01 | 2018-04-28 | ||
RU2543485C2 (en) * | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Heterocyclic tgr5 bile acid receptor agonists, pharmaceutical composition, methods for preparing and using them |
CN104844535A (en) * | 2014-02-13 | 2015-08-19 | 吉利德科学公司 | Method for preparing condensed heterocyclic ion channel conditioning agent |
MA40082B1 (en) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | New Sphingosine Phosphate Substitution Compound Useful Treatment Disease Rheumatism |
EP3227263B1 (en) * | 2014-12-01 | 2019-04-10 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
WO2022173795A1 (en) * | 2021-02-10 | 2022-08-18 | Icahn School Of Medicine At Mount Sinai | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS |
WO2023081328A1 (en) * | 2021-11-04 | 2023-05-11 | Valo Health, Inc. | Histone deacetylase 6 inhibitor compounds and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3964478B2 (en) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same |
JPH1180026A (en) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | New immunosuppressant, its use and its identification |
US7429579B2 (en) | 2000-11-14 | 2008-09-30 | Smithkline Beecham, Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
AU2004249664A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
AU2004277947A1 (en) * | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
WO2005058848A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
US8039674B2 (en) * | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
GB0414795D0 (en) | 2004-07-01 | 2004-08-04 | Glaxo Group Ltd | Compounds |
JP2008517915A (en) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | 2- (Aryl) azacyclylmethylcarboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
JP4318087B2 (en) | 2004-12-13 | 2009-08-19 | 小野薬品工業株式会社 | Aminocarboxylic acid derivatives and their pharmaceutical use |
ES2365747T3 (en) * | 2005-03-23 | 2011-10-10 | Actelion Pharmaceuticals Ltd. | BENZO [C] THIOPHENE HYDROGEN DERIVED AS IMMUNOMODULATORS. |
US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
KR20070121013A (en) * | 2005-04-22 | 2007-12-26 | 다이이찌 산쿄 가부시키가이샤 | Heterocyclic compound |
WO2006131336A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
CA2619101A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
TW200738694A (en) | 2005-11-24 | 2007-10-16 | Glaxo Group Ltd | Chemical compounds |
CA2648303C (en) * | 2006-04-03 | 2014-07-15 | Astellas Pharma Inc. | 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists |
EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
-
2008
- 2008-12-18 PE PE2008002122A patent/PE20091339A1/en not_active Application Discontinuation
- 2008-12-19 EP EP08864021.4A patent/EP2222669B1/en active Active
- 2008-12-19 TW TW097149553A patent/TWI415847B/en not_active IP Right Cessation
- 2008-12-19 RS RS20130479A patent/RS53038B/en unknown
- 2008-12-19 AU AU2008339988A patent/AU2008339988B2/en not_active Expired - Fee Related
- 2008-12-19 BR BRPI0820131 patent/BRPI0820131A2/en not_active IP Right Cessation
- 2008-12-19 JP JP2010538741A patent/JP2011506569A/en active Pending
- 2008-12-19 KR KR1020107016167A patent/KR20100108566A/en not_active Application Discontinuation
- 2008-12-19 WO PCT/EP2008/067965 patent/WO2009080725A1/en active Application Filing
- 2008-12-19 PL PL08864021T patent/PL2222669T3/en unknown
- 2008-12-19 DK DK08864021.4T patent/DK2222669T3/en active
- 2008-12-19 UY UY31570A patent/UY31570A1/en unknown
- 2008-12-19 AR ARP080105590A patent/AR069916A1/en not_active Application Discontinuation
- 2008-12-19 ES ES08864021T patent/ES2434730T3/en active Active
- 2008-12-19 NZ NZ585996A patent/NZ585996A/en not_active IP Right Cessation
- 2008-12-19 CN CN2008801273456A patent/CN101945863B/en not_active Expired - Fee Related
- 2008-12-19 EA EA201070782A patent/EA017691B1/en not_active IP Right Cessation
- 2008-12-19 SI SI200831050T patent/SI2222669T1/en unknown
- 2008-12-19 US US12/747,205 patent/US8222245B2/en not_active Expired - Fee Related
- 2008-12-19 CA CA2710130A patent/CA2710130A1/en not_active Abandoned
- 2008-12-19 PT PT88640214T patent/PT2222669E/en unknown
-
2009
- 2009-01-28 US US12/360,886 patent/US20100174065A1/en not_active Abandoned
-
2010
- 2010-06-03 ZA ZA2010/03963A patent/ZA201003963B/en unknown
- 2010-06-07 IL IL206235A patent/IL206235A0/en unknown
- 2010-06-16 MA MA32926A patent/MA31924B1/en unknown
- 2010-06-21 CO CO10074455A patent/CO6290646A2/en active IP Right Grant
- 2010-06-21 DO DO2010000194A patent/DOP2010000194A/en unknown
- 2010-07-21 CR CR11579A patent/CR11579A/en not_active Application Discontinuation
- 2010-09-03 HK HK10108378.3A patent/HK1142062A1/en not_active IP Right Cessation
-
2013
- 2013-10-09 HR HRP20130957AT patent/HRP20130957T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0820131A2 (en) | Sphingosine-1-phosphate active oxadiazole derivatives (s1p) | |
CY2020036I2 (en) | DOSAGE FORMS FOR AN S1P RECEPTOR AGENT | |
CY2018004I1 (en) | SUBSTITUTED OXAZOLIDINONE COMBINATION THERAPY | |
BRPI0818457A2 (en) | OXADIAZOL DERIVATIVES | |
PT2003132E (en) | Oxadiazole derivatives as s1p1 agonists | |
DE602008005285D1 (en) | OXADIAZOLSUBSTITUTED INDAZONE DERIVATIVES FOR USE AS SPHINGOSINE-1-PHOSPHATE (S1P) -AGONISTS | |
BRPI1013422A2 (en) | oxadiazole derivatives | |
DK2102205T3 (en) | Pyridopyrazine derivatives useful as herbicidal compounds | |
DK2021335T3 (en) | Heterocyclic compounds as C-FMS kinase inhibitors | |
DK2300459T3 (en) | NEW PHENYL PYRAZINONES AS KINase INHIBITORS | |
DK2152712T3 (en) | AMINO HETEROCYCLIC PHO CONNECTIONS | |
BRPI0818161A2 (en) | compositions comprising sphingosine-1-phosphate (s1p) receptor modulators | |
IL200634A0 (en) | Insecticidal aryl isoxazoline derivatives | |
BRPI0922464A2 (en) | Active compound combinations | |
BRPI0906705A2 (en) | Heterocyclic Compounds | |
IL206278A0 (en) | Oxadiazole derivatives active on sphingosine-1-phosphate (s1p) | |
EP2196459A4 (en) | 5-membered heterocyclic compound | |
DE112007001970A5 (en) | Machine housing of an electrical machine | |
DK2308869T3 (en) | azole compound | |
FIU20100142U0 (en) | Arrangement for powering | |
HK1189591A1 (en) | Hydrochloride salt of 5-r3-f3-tivdroxyphenoxy)azetidi-1-v-5-methyl-2 2- diphenylhexanamide 5-[3-(3-)-1-]-5--22- | |
BR112013013648A2 (en) | phenyl oxadiazole derivatives as sphingosine-1-phosphate receptor modulators (s1p) | |
BRPI0923178A2 (en) | fused heterocyclic oxadiazole derivatives useful for treating multiple sclerosis | |
DE112007001996A5 (en) | Machine housing of an electrical machine | |
DE602007003680D1 (en) | Anesthesia machine arrangement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |